Thymopentin in the treatment of severe alopecia areata

Antonella Tosti, P. Manuzzi, A. Gasponi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata.

Original languageEnglish
Pages (from-to)170-174
Number of pages5
JournalDermatologica
Volume177
Issue number3
StatePublished - Jan 1 1988
Externally publishedYes

Fingerprint

Thymopentin
Alopecia Areata
Cellular Immunity
Therapeutics
T-Lymphocytes
Pharmaceutical Preparations
squaric acid
diphenylcyclopropenone

ASJC Scopus subject areas

  • Dermatology

Cite this

Tosti, A., Manuzzi, P., & Gasponi, A. (1988). Thymopentin in the treatment of severe alopecia areata. Dermatologica, 177(3), 170-174.

Thymopentin in the treatment of severe alopecia areata. / Tosti, Antonella; Manuzzi, P.; Gasponi, A.

In: Dermatologica, Vol. 177, No. 3, 01.01.1988, p. 170-174.

Research output: Contribution to journalArticle

Tosti, A, Manuzzi, P & Gasponi, A 1988, 'Thymopentin in the treatment of severe alopecia areata', Dermatologica, vol. 177, no. 3, pp. 170-174.
Tosti A, Manuzzi P, Gasponi A. Thymopentin in the treatment of severe alopecia areata. Dermatologica. 1988 Jan 1;177(3):170-174.
Tosti, Antonella ; Manuzzi, P. ; Gasponi, A. / Thymopentin in the treatment of severe alopecia areata. In: Dermatologica. 1988 ; Vol. 177, No. 3. pp. 170-174.
@article{454ec6ab002e4bfaa2c7a7f8eea8b719,
title = "Thymopentin in the treatment of severe alopecia areata",
abstract = "Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata.",
author = "Antonella Tosti and P. Manuzzi and A. Gasponi",
year = "1988",
month = "1",
day = "1",
language = "English",
volume = "177",
pages = "170--174",
journal = "Dermatology",
issn = "1018-8665",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Thymopentin in the treatment of severe alopecia areata

AU - Tosti, Antonella

AU - Manuzzi, P.

AU - Gasponi, A.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata.

AB - Since alopecia areata might be due to an aberrant T-cell-mediated immunity, the purpose of our study was to compare the results obtained with Thymopentin to those of topical sensitizing therapies, such as squaric acid dibutylester or diphencyprone. Statistical analysis showed no differences between the results obtained with these two therapies. Therefore, Thymopentin can be considered to be a new therapeutic agent which, like the classic topical drugs squaric acid dibutylester or diphencyprone, has immunoreactive properties and might provide some hope to patients with severe alopecia areata.

UR - http://www.scopus.com/inward/record.url?scp=0023677556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023677556&partnerID=8YFLogxK

M3 - Article

C2 - 3049174

AN - SCOPUS:0023677556

VL - 177

SP - 170

EP - 174

JO - Dermatology

JF - Dermatology

SN - 1018-8665

IS - 3

ER -